Science Pool

The Future of MEA in Early Toxicology Assessment

It is almost 50 years since MEA was first developed, however, the power of this technology in toxicology testing has only just been realised due to the introduction of the multi-well MEA allowing for its utility in high throughput

In this whitepaper, we focus on:

  • the current challenges within the pharmaceutical industry in terms of toxicology prediction
  • how companies are addressing these challenges using human relevant cell-based models
  • an in-depth evaluation of microelectrode array (MEA) and its key role in in vitro cardiotoxicity and neurotoxicity toxicology testing

Read our whitepaper to learn more!

Sounds interesting?
Enter your details below to continue reading…

By clicking on ‘Continue’ I agree that my data is being transferred to the Evotec Group. The Evotec Group currently consists of the following companies. For further details please see our Privacy Policy.

If you would like to be kept informed of our latest services, new research, events and other news please tick the box below:

Join our community

Discover the exclusive benefits on offer if you join our community.